The deal encompasses WoundSkan, a temperature-sensing smart dressing, and the Spektra Lateral Flow Test, a multi-marker screening platform. Davion leadership maintains that both assets fit their strategic focus on battery-free, smartphone-integrated health monitoring. This acquisition represents the company's first major move since its direct listing on the Nasdaq Global Market just last week.

To fund the purchase, Davion paid $2.5 million in cash and issued approximately 1.7 million new ordinary shares. The stock portion of the deal was valued at a fixed contractual price of $13 per share, totaling $22.5 million. Chief Executive Glenn Williams stated the firm is now positioned to accelerate the development and commercialization of these technologies while scouting for additional growth opportunities.